Biopharmaceutical Investment Program (BIP) 

Next Generation of Jobs Fund - Biopharmaceutical Investment Program (BIP) Overview

BIP is aimed at attracting new or enhanced biopharmaceutical investments in Ontario.  $150 million will be available over the next 5 years.  BIP is the first component of the Government of Ontario’s $1.15 billion Next Generation of Jobs Fund strategy and will fund up to 20% of total eligible project costs.

BIP Objectives:

• To increase the level of new biopharmaceutical Research and Development and advanced manufacturing in Ontario
• To expand local footprints, and create a generation of new high value jobs for Ontarians
• To increase “deal flow” within Ontario’s growing biotech cluster, and build capacity through collaborations with public research institutions

Eligibility Checklist:

Please see the Program Guidelines document for details of eligibility criteria, including definitions of drugs, baseline investment, advanced manufacturing, etc. as relevant to BIP.

	Your company’s primary source of business comes from patented products that have received marketing approval by way of a Health Canada New Drug Submission or the equivalent submission in the United States, the European Union or Japan.
	Your company holds at least one patented human health drug product approved for sale in one or more of the following markets: Canada, the United States, the European Union, and/or Japan. (Contract manufacturers and contract research firms under contract with such companies may also apply.)
	Your proposed project will see an incremental increase to your R&D investment in Ontario; and/or your proposed project is for a new advanced manufacturing project in Ontario.
	Your proposal is related to R&D and/or advanced manufacturing of innovative drugs.
	Your project will be situated at a facility/facilities in Ontario.
	Your project has minimum total eligible project costs of $5M.
	Your proposal does not request funding for R&D and/or manufacturing related to medical devices, non-human health products, human non-medical products (e.g. products that are not/would not be prescribed by a medical practitioner), or for business restructuring or regular capital reinvestment

  

How to Apply:

The BIP is a continuous flow program with no discreet funding rounds. 

The Ministry of Research and Innovation is committed to making timely decisions on all Full Applications once submitted.

1st Stage: potential BIP Applicants are required to submit an Expression of Interest Form.

• Potential applicants are encouraged to utilize the “Project Assessment Tool” highlighted in the Program Guidelines to review their proposed project prior to submission of an EoI.
• The Project Assessment Tool allows for the testing of a concept or idea for a potential submission to the BIP as it provides details of the criteria used by the Ministry of Research and Innovation to review applications to this program.
• This will enable an applicant to determine whether to apply to the BIP and, if so, ways to strengthen the application.
• Please note that a high rating on the Project Assessment Tool does not guarantee that an application will be approved as any approval is at the ministry’s discretion.

2nd Stage: applicants invited to do so are required to submit a Full Application Form. The template will be provided to the applicant by MRI at that time.

Select the following links to download:

Program Guidelines (PDF File - 95 KB)
Application Guide (Word - 56 KB)
EoI Template (Word - 119 KB)

For further assistance regarding the Biopharmaceutical Investment Program (BIP), please contact the Ministry of Research and Innovation as follows.

Contact: 

Biopharmaceutical Investment Program (BIP)
Pharmaceutical Innovation Secretariat
Outreach, Promotion and Business Development Branch
Ministry of Research and Innovation
18th Floor, 56 Wellesley St. W.
Toronto, ON  M7A 2E7
Tel: 1-800-819-8701 (North America)
00-800-46-68-27-46 (U.K. and Europe)
00-800-46-68-27-46 (Japan (ITJ))
0061-800-46-68-27-46 (Japan (KDD))
E-mail: info@2ontario.com

>>> Continue to Program Guidelines